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ABSTRACT
The aim of the present study was to examine the relationship between tumour 
1)ǉ%DFWLYDWLRQWXPRXUPLFURHQYLURQPHQWLQFOXGLQJORFDOLQÀDPPDWRU\UHVSRQVH
/,5DQGFDQFHUVSHFL¿FVXUYLYDOLQSDWLHQWVZLWKRSHUDEOHGXFWDOEUHDVWFDQFHU

















important determinant of poor outcome in patients with invasive ductal breast cancer.
INTRODUCTION
Breast cancer is the most common female cancer 
in the UK and, despite earlier detection and improved 
treatments, remains the second most common cause of 
cancer death in women [1, 2]. Therefore, it is clear that a 
further understanding of this disease process is required.
For many years an association between cancer and 
LQÀDPPDWLRQKDVEHHQVXVSHFWHGDQGHYLGHQFHKDVEHHQ
gathered over the last decade to support this relationship [3, 
4]. However, little is known about the signalling pathways 
that link these processes. The canonical mammalian Nuclear 
)DFWRUNDSSD%1)ț%SDWKZD\UHJXODWHVJHQHVLQYROYHG
in many of the processes considered as hallmarks of cancer 
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





$EHUUDQW DFWLYLW\ RI YDULRXV 1)ț% FRPSRQHQWV
has been observed in a number of solid tumours including 
FRORUHFWDO >@ DQG SURVWDWH FDQFHU >±@ ,Q EUHDVW
FDQFHULQFUHDVHG1)ț%DFWLYLW\KDVEHHQREVHUYHGLQUDW
mammary tumours compared to normal tissue [14] and 
numerous studies employing cell lines have reported an 
DVVRFLDWLRQZLWK1)ț%DFWLYLW\ DQG HQGRFULQH UHVLVWDQFH
>@,QKXPDQEUHDVWFDQFHUVSHFLPHQVH[SUHVVLRQRIWKH










Therefore the aims of the present study are to 
H[DPLQH WKH UHODWLRQVKLS EHWZHHQ NH\ PHPEHUV RI WKH
FDQRQLFDO1)ț%SDWKZD\,..ĮDQGS5HO$ORFDO
LQÀDPPDWRU\LQ¿OWUDWHDQGVXUYLYDOLQDFRKRUWRISDWLHQWV
with primary operable invasive ductal breast cancer.
RESULTS
$WRWDORISDWLHQWVZKRSUHVHQWHGZLWKLQYDVLYH
ductal breast cancer were included in the study. Seventy 
three patients had local or distant recurrences, the median 
IROORZXS RI VXUYLYRUV ZDV  PRQWKV ZLWK  FDQFHU
DVVRFLDWHGGHDWKVDQGQRQFDQFHUGHDWKV(535+(5
DQG.LVWDWXVZDVDYDLODEOH IRU WKHVHSDWLHQWVDOORZLQJ







of cases due to missing data.
([SUHVVLRQRI,..ȕZDVREVHUYHGLQWKHF\WRSODVP
DQG UDQJHG IURP  ZHLJKHG KLVWRVFRUH XQLWV
6XSSOHPHQWDU\)LJXUH3SH[SUHVVLRQZDVREVHUYHG
in the cytoplasm ranging from 0-220 histoscore units and the 
QXFOHXVUDQJLQJIURPKLVWRVFRUHXQLWV6XSSOHPHQWDU\
)LJXUH([SUHVVLRQZDVVSOLWLQWRWHUWLOHVWKH¿UVWWHUWLOH
ZDV FRQVLGHUHG ORZ H[SUHVVLRQ DQG WKH VHFRQG DQG WKLUG
tertiles were grouped to provide a measure of moderate/high 
H[SUHVVLRQ ([SUHVVLRQ RI ,..ȕ ZDV QRW DVVRFLDWHG ZLWK
FDQFHUVSHFL¿FVXUYLYDO)LJXUH$3 F\WRSODVPLF
SSH[SUHVVLRQ VKRZHGDQRQVLJQL¿FDQW WUHQG WRZDUGV





:KHQ SDWLHQWV ZHUH VXEGLYLGHG E\ PROHFXODU







IURP  WR  3 $ WUHQG WRZDUGV FDQFHU
VSHFL¿F VXUYLYDO ZDV REVHUYHG LQ WKH WULSOH QHJDWLYH











VXEW\SH 7DEOH  :KHQ DVVRFLDWLRQV ZLWK WKH WXPRXU
PLFURHQYLURQPHQW ZHUH LQYHVWLJDWHG QXFOHDU SS
H[SUHVVLRQZDVQRWVLJQL¿FDQWO\DVVRFLDWHGZLWKWXPRXU
budding, T-lymphocytes or Klintrup-Makinen grade. 
However an association was observed with increasing 
WXPRXUVWURPDOSHUFHQWDJH3 7DEOH
:KHQQXFOHDUSSZDVHQWHUHGLQWRDPXOWLYDULDWH
model using a backwards conditional method with 
FOLQLFRSDWKRORJLFDOSDUDPHWHUVQXFOHDUSSH[SUHVVLRQ
ZDV QRW LQGHSHQGHQWO\ DVVRFLDWHG ZLWK FDQFHUVSHFL¿F
VXUYLYDOLQWKHIXOOFRKRUW7DEOHEXWZDVLQGHSHQGHQWO\
DVVRFLDWHG ZLWK FDQFHUVSHFL¿F VXUYLYDO LQ /XPLQDO %
GLVHDVH3 +5
7R H[DPLQH WKH UHODWLRQVKLS RI FDQFHUVSHFL¿F




patients with either moderate/high cytoplasmic or nuclear 
H[SUHVVLRQZHUHFODVVL¿HGDVWKHPRGHUDWHKLJKH[SUHVVLRQ
JURXS 0RGHUDWHKLJK H[SUHVVLRQ RI WRWDO WXPRXU FHOO
H[SUHVVLRQ RI SS ZDV VLJQL¿FDQWO\ DVVRFLDWLRQ ZLWK






ORVW LQ SDWLHQWV ZLWK /XPLQDO $ GLVHDVH )LJXUH %
3   \HDU VXUYLYDO  YUV  3 
DQGLQSDWLHQWVZLWK+(5HQULFKHGGLVHDVH)LJXUH(
3   \HDU VXUYLYDO  YUV  3 
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model and tumour characteristics was subsequently 
H[DPLQHG7DEOH+LJKH[SUHVVLRQRIWRWDOWXPRXUFHOO
H[SUHVVLRQ RI SS ZDV DVVRFLDWHG ZLWK D KLJK WXPRXU
JUDGH3 (5SRVLWLYHGLVHDVH3 PROHFXODU
VXEW\SH3 DQGWXPRXUUHFXUUHQFH3 :KHQ
associations with the tumour microenvironment were 
LQYHVWLJDWHG KLJK WRWDO WXPRXU FHOO H[SUHVVLRQ ZDV QRW
VLJQL¿FDQWO\DVVRFLDWHGZLWK WXPRXUVWURPDOSHUFHQWDJH
tumour budding or T-lymphocytes. However an association 
ZDV REVHUYHG ZLWK ORFDO LQÀDPPDWRU\ FHOO LQ¿OWUDWH DV
DVVHVVHGE\.OLQWUXS0DNLQHQJUDGH3 DQGGHQVLW\
RI&'+%O\PSKRF\WHV3 
:KHQ WRWDO WXPRXU FHOO SS ZDV HQWHUHG LQWR D







FDQRQLFDO 1)ț% SDWKZD\ PHDVXUHG E\ QXFOHDU SS







,W ZDV ¿UVW HVWDEOLVKHG WKDW WKH FDQRQLFDO 1)ț%





DQG FDQFHUVSHFL¿F VXUYLYDO LQ SDWLHQWV ZLWK /XPLQDO$ LQYDVLYH GXFWDO EUHDVW FDQFHU 3  (E) shows the relationship between 
QXFOHDUSSH[SUHVVLRQDQGFDQFHUVSHFL¿FVXUYLYDOLQSDWLHQWVZLWK/XPLQDO%LQYDVLYHGXFWDOEUHDVWFDQFHU3 (F) shows the 
UHODWLRQVKLSEHWZHHQQXFOHDUSSH[SUHVVLRQDQGFDQFHUVSHFL¿FVXUYLYDOLQSDWLHQWVZLWKWULSOHQHJDWLYHLQYDVLYHGXFWDOEUHDVWFDQFHU
3  (G) VKRZV WKH UHODWLRQVKLSEHWZHHQQXFOHDUSSH[SUHVVLRQ DQGFDQFHUVSHFL¿F VXUYLYDO LQSDWLHQWVZLWK+(5HQULFKHG
LQYDVLYHGXFWDOEUHDVWFDQFHU3 
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DFKLHYHG E\ WUHDWLQJ WKH FHOOV ZLWK 71)Į ZKLFK LV
NQRZQ WR VWLPXODWH WKH FDQRQLFDO SDWKZD\ ,Q 0&)
(5SRVLWLYHEUHDVWFDQFHUFHOOV71)ĮH[SRVXUHLQGXFHG
,ț%Į GHJUDGDWLRQ DQG SKRVSKRU\ODWLRQ RI S LQ D
WLPH GHSHQGHQW PDQQHU )LJXUH $ )ROORZLQJ 71)Į











PLQXWHV /HYHOV RI S DQG ,..ȕ ZHUH XQFKDQJHG E\
71)ĮH[SRVXUH
+DYLQJ HVWDEOLVKHG WKDW WKH FDQRQLFDO 1)ț%
pathway was active in both cell types, and inducible to 
D PXFK JUHDWHU H[WHQW LQ 0&) FHOOV WKH QH[W DLP RI
the study was to assess the impact on cell viability by 
LQKLELWLQJWKHSDWKZD\YLDVLOHQFLQJRI,..ȕ
0&) DQG 0'$0% FHOOV ZHUH WUDQVIHFWHG
ZLWKQ0QRQWDUJHWLQJ17VL51$RUQ0,..ȕ








$JH!\HDUV   
6L]H!PP   1.000
*UDGH,,,,,,   
,QYROYHGO\PSKQRGHQHJDWLYHSRVLWLYH  134/111 
(5VWDWXVQR\HV 44/82  
35VWDWXVQR\HV   
+(5VWDWXVQR\HV 100/23  
Molecular subtype (Luminal A/Luminal B/triple 
QHJDWLYH+(5HQULFKHG
  
7XPRXUQHFURVLVORZKLJK   
/\PSKYHVVHOLQYDVLRQQR\HV   
%ORRGYHVVHOLQYDVLRQQR\HV 108/18 221/28 
.OLQWUXS±0lNLQHQJUDGHZHDNVWURQJ   0.444
&'ORZPRGHUDWHKLJK   
&'ORZPRGHUDWHKLJK   
&'ORZPRGHUDWHKLJK   
&'ORZPRGHUDWHKLJK   0.382
$QJLRJHQHVLVORZPRGHUDWHKLJK   
7XPRXUVWURPDSHUFHQWDJHORZKLJK 82/42 138/110 





Systemic treatment (hormonal/hormonal+ 
FKHPRWKHUDS\FKHPRWKHUDS\QRQH
  
5HFXUUHQFHQRUHFXUUHQFHUHFXUUHQFH 104/20  
%ROGLQGLFDWHVDVLJQL¿FDQWDVVRFLDWLRQ1XPEHURISDWLHQWVZLWKPLVVLQJGDWDLVQRWGLVSOD\HGZKHQYDOXHVGRQRWJLYHD
sum of 100% this is due to data being unavailable.
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RU FHOO YLDELOLW\ DVVD\ ZDV SHUIRUPHG )LJXUH $ $
VLJQL¿FDQW LQFUHDVH LQ DSRSWRVLV ZDV REVHUYHG LQ FHOOV
WUHDWHG ZLWK VL51$ WR VLOHQFH H[SUHVVLRQ RI ,..ȕ
FRPSDUHGWRWKH17FRQWURO0&)FHOOV3[ and 
0'$0%FHOOV3 [-4)LJXUH%DQGDGHFUHDVH
in cell viability was observed in cells treated with siRNA 
WRVLOHQFHH[SUHVVLRQRI,..ȕFRPSDUHGWRWKH17FRQWURO








,Q WKH SUHVHQW VWXG\ H[SUHVVLRQ RI NH\ PHPEHUV
RI WKH FDQRQLFDO 1)ț% SDWKZD\ ZHUH LQYHVWLJDWHG WR
HVWDEOLVKLIWKHUHZDVDOLQNEHWZHHQWKHFDQRQLFDO1)Ƹ%
SDWKZD\ORFDOLQÀDPPDWRU\LQ¿OWUDWHDQGFDQFHUVSHFL¿F
survival in a cohort of patients with primary operable 
LQYDVLYHGXFWDOEUHDVWFDQFHU3KRVSKRU\ODWLRQRISDW
VHULQHSSZDVHPSOR\HGDVDPDUNHURIDFWLYDWLRQ
RI WKH FDQRQLFDO 1)ț% SDWKZD\ DV LW LV LPSRUWDQW IRU
WUDQVFULSWLRQDO DFWLYDWLRQRI WKH1)Ƹ%GLPHU >@
+LJK H[SUHVVLRQ RI SS LQ WKH F\WRSODVP H[KLELWHG



















QR\HV    0.001  
(5VWDWXVQR\HV  0.001
35VWDWXVQR\HV    0.002  0.002
+(5VWDWXVQR\HV  0.002
7XPRXUQHFURVLVORZKLJK      
Lymph vessel invasion 
QR\HV  
Blood vessel invasion 





&'ORZPRGHUDWHKLJK  0.001    
&'ORZPRGHUDWH
KLJK  0.01    
Tumour stroma percentage 
ORZKLJK    0.002  0.002
7XPRXUEXGGLQJORZKLJK    0.002  
1XFOHDUSSORZKLJK     NA NA
7RWDO7XPRXUFHOOSS
ERWKORZRQHKLJK   NA NA  0.024
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DVVRFLDWHGZLWKSDWLHQWFDQFHUVSHFL¿FVXUYLYDOUHFXUUHQFH
and tumour grade. However no associations were made 
ZLWKQXFOHDUSSDQGLQÀDPPDWRU\LQ¿OWUDWHVXJJHVWLQJ
that this pathway is not responsible for regulating the 
ORFDO LQÀDPPDWRU\ UHVSRQVHEXWSHUKDSVDFWLQJYLDDQ
alternative mechanism such as proliferation.
Of additional interest was the observation that 
QXFOHDUSSZDVPRVWVWURQJO\DVVRFLDWHGZLWKFDQFHU
VSHFL¿FVXUYLYDOLQ(5SRVLWLYH/XPLQDO%WXPRXUV7KHUH
are four main subtypes of breast cancer that are considered 
clinically relevant (Luminal A, Luminal B, HER2 
HQULFKHGDQGWULSOHQHJDWLYH$OOVXEW\SHVKDYHGLIIHUHQW
PROHFXODU SUR¿OHV DQG YDULHG UHVSRQVHV WR HQGRFULQH
therapy, HER2 targeted therapy and chemotherapy [3]. 
'LIIHUHQFHVLQWKHELRORJ\RIWKHVHVXEW\SHVDUHUHÀHFWHG
LQWKHUHVXOWVIURPWKLVVWXG\DVDFWLYDWLRQRIWKH1)ț%
pathway has diverging roles in the different subtypes. 
The present study demonstrates that the association of 
QXFOHDU SS H[SUHVVLRQ ZLWK FDQFHUVSHFL¿F VXUYLYDO
observed in the full cohort is negated in patients with ER 
positive Luminal A tumours but potentiated in patients 
with ER positive Luminal B tumours, indicating that this 
association is independent of ER status. This observation 
adds to the growing body of evidence that Luminal A 
and Luminal B breast cancers should be considered as 
different diseases and may require separate therapeutic 
DSSURDFKHV&XUUHQWO\ERWKWKHVHSDWLHQWJURXSVUHFHLYH
endocrine therapy, with Luminal B patients having a worse 
prognosis, which is associated with an increased rate of 
endocrine resistance. The increased rate of endocrine 
resistance has previously been attributed to the presence 
of HER2 in this subtype, providing an alternative-
signalling pathway to escape the inhibitory effects of 
endocrine therapy. However, not all patients with Luminal 
%GLVHDVHH[KLELWRYHUH[SUHVVLRQRI+(5VXJJHVWLQJWKDW
the increased rate in endocrine recurrence in Luminal B 
disease might have been not be solely attributed to HER2 
and might be due to an alternative mechanism in HER2 





H[SUHVVLRQDQGFDQFHUVSHFL¿FVXUYLYDOLQSDWLHQWVZLWK/XPLQDO%LQYDVLYHGXFWDOEUHDVWFDQFHU3 (D) shows the relationship 
EHWZHHQ WRWDO WXPRXU FHOO SSH[SUHVVLRQ DQG FDQFHUVSHFL¿F VXUYLYDO LQSDWLHQWVZLWK7ULSOHQHJDWLYH LQYDVLYHGXFWDO EUHDVW FDQFHU










$JH!\HDUV   
6L]H!PP 40/31/2  
*UDGH,,,,,,   
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Molecular subtype (Luminal A/Luminal B/triple 
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  
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 32/40  0.813
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 18/31/24 81/108/112 0.840
&'ORZPRGHUDWHKLJK   
7XPRXUVWURPDSHUFHQWDJHORZKLJK   





Systemic treatment (hormonal/hormonal+ 
FKHPRWKHUDS\FKHPRWKHUDS\QRQH   0.244
5HFXUUHQFHQRUHFXUUHQFHUHFXUUHQFH   
Bold indicates a signicant association. Number of patients with missing data is not displayed, when values do not give a sum 




UDWH .L ! RU +(5 SRVLWLYLW\ 7R LQYHVWLJDWH
if the increased rate of recurrence observed in Luminal 
B patients in the current study can be fully attributed to 
+(5GHSHQGHQF\ DQGQRW1)ț%SDWKZD\DFWLYDWLRQ
patients with Luminal B tumours were further divided 
LQWRWKRVHZLWK+(5SRVLWLYHWXPRXUVRUKLJK.L7KH
UHODWLRQVKLSZLWKSSDQGFDQFHUVSHFL¿FVXUYLYDOZDV
maintained in highly proliferative tumours and not in those 
with HER2 positive tumours. Only very small numbers 
were available for analysis, so this observation should be 
FRQ¿UPHGLQDODUJHUFRKRUWEXWGRHVVXJJHVWWKDWLQWKH
KLJK .L VXEJURXS DFWLYDWLRQ RI WKH 1)ț% SDWKZD\
may also play a role in the increased rate of recurrence 
attributed to development of endocrine resistance. This in 
LWVHOI LVQRWDQRYHOREVHUYDWLRQDV WKH1)ț%SDWKZD\
has previously been associated with development of 





proliferative tumours, offering an alternative therapeutic 
strategy for patients with HER2 negative Luminal B 
disease. This approach may be employed in combination 
with endocrine treatment to delay development of 
endocrine resistance or as a therapeutic option following 
development of endocrine resistance.
To further investigate this hypothesis mechanistic 
VWXGLHVH[DPLQLQJWKHHIIHFWDQGPRVWHI¿FLHQWPHWKRGRI
VXSSUHVVLQJDFWLYDWLRQRI1)ț%SDWKZD\VDUHUHTXLUHG










viability, using various methods, including assessment 
RI DSRSWRVLV XVLQJ DQ (/,6$ YLDELOLW\ XVLQJ D:67
DVVD\UHDOWLPHJURZWKDQGYLDELOLW\XVLQJ[&(//LJHQFH
FHOO LQGH[$OO PRGHV RI DVVHVVPHQW GHPRQVWUDWHG WKDW
UHGXFWLRQ LQ ,..ȕ H[SUHVVLRQ UHVXOWHG LQ D GHFUHDVH
of cell viability. These results taken together with our 
FOLQLFDOFRKRUWUHVXOWVVXJJHVWWKDWLWPD\EHEHQH¿FLDOWR
EORFN1)ț%DFWLYLW\LQ(5SRVLWLYH/XPLQDO%SDWLHQWV
in combination with endocrine therapy or following 
development of endocrine resistance.
Although the effect we observed was potentiated 
in patients with ER positive, Luminal B disease, a trend 
WRZDUGVVLJQL¿FDQFHZDVDOVRREVHUYHGLQSDWLHQWVZLWK
(535+(5QHJDWLYHWULSOHQHJDWLYHGLVHDVHEXWQRW
ER negative, HER2 enriched disease. Although the trend 
GLGQRWUHDFKVLJQL¿FDQFHLQSDWLHQWVZLWKWULSOHQHJDWLYH
GLVHDVH  \HDU FDQFHUVSHFL¿F VXUYLYDO ZDV VWUDWL¿HG
IURPWR6LJQL¿FDQFHZDVSRVVLEO\QRWPHWGXH
to the study being underpowered to observe differences in 
this subtype. This is also in concordance with the in vitro 




This is in line with the literature where high levels of 
1)Ƹ% DFWLYLW\ KDYH EHHQ UHSRUWHG LQ (5QHJDWLYH
tumours [28].
,Q DGGLWLRQ WR LQYHVWLJDWLQJ DVVRFLDWLRQV EHWZHHQ
QXFOHDUSSH[SUHVVLRQDQGSDWLHQWRXWFRPHPHDVXUHVD
cumulative prognostic score combining both cytoplasmic 
DQGQXFOHDUSSZDVH[DPLQHG8VLQJWKLVFXPXODWLYH
prognostic score the current study observed that total cell 
H[SUHVVLRQ ZDV D VWURQJHU SUHGLFWRU RI FDQFHUVSHFL¿F
survival compared to nuclear alone and was independently 
DVVRFLDWHGZLWKFDQFHUVSHFL¿FVXUYLYDOZKHQFRPELQHG
ZLWKFOLQLFRSDWKRORJLFDOSDUDPHWHUV ,QDGGLWLRQ WR WKH




with tumour grade, tumour stroma percentage, recurrence 
DQGFDQFHUVSHFL¿FVXUYLYDOLQFRPSDULVRQWRWRWDOWXPRXU
FHOOSSEHLQJDVVRFLDWHGZLWKWXPRXUJUDGH(5VWDWXV
PROHFXODU VXEW\SH .OLQWUXS0DNLQHQ JUDGH &'
FHOOV UHFXUUHQFH DQG FDQFHUVSHFL¿F VXUYLYDO 7KLV
VXJJHVWVWKDWH[DPLQLQJWRWDOFHOOSSH[SUHVVLRQUHVXOWV
in a more accurate, robust measurement of activated 
1)Ƹ%LQ WKH WXPRXUFHOOSULRU WRRUIROORZLQJQXFOHDU
WUDQVORFDWLRQ7KHUHIRUHWRWDOWXPRXUFHOOSSPD\EH
employed as a possible prognostic marker, or predictive 
PDUNHUIRUWKHUDSLHVWDUJHWLQJ1)Ƹ%:KHQVWUDWL¿HGE\
PROHFXODU VXEW\SH DOWKRXJK QRW UHDFKLQJ VLJQL¿FDQFH
D WUHQG ZDV REVHUYHG EHWZHHQ UHGXFHG FDQFHUVSHFL¿F
VXUYLYDODQGWRWDOWXPRXUFHOOSSLQWKH/XPLQDO%DQG
triple negative subtypes, in line with that observed for 
QXFOHDUSS
,Q VXPPDU\ UHVXOWV IURP WKH SUHVHQW VWXG\
GHPRQVWUDWH D VLJQL¿FDQW UROH RI WKH FDQRQLFDO 1)ț%
pathway in the progression of breast cancer, which appears 
to be greater in Luminal B and triple negative subtypes. 
6HOHFWLYH QRYHO FRPSRXQGV WDUJHWLQJ 1)Ƹ% SDWKZD\
may offer a promising therapeutic approach. Furthermore, 
clinical trials should be designed incorporating predictive 





The TMA included tumour tissue samples from 
EUHDVWFDQFHUSDWLHQWVSUHVHQWLQJZLWKLQYDVLYHGXFWDO
EUHDVW FDQFHU EHWZHHQ  DQG  LQ WKH :HVW RI
6FRWODQGDW*ODVJRZ5R\DO,Q¿UPDU\*ODVJRZ:HVWHUQ
,Q¿UPDU\ DQG 6WREKLOO +RVSLWDO &OLQLFRSDWKRORJLFDO
GDWDDYDLODEOHLQFOXGHGDJHWXPRXUJUDGHWXPRXUVL]H
O\PSKQRGHVWDWXVWKHUDS\(535DQG+(5VWDWXVDQG





DQGEORRGYHVVHO LQYDVLRQ /9,DQG%9, UHVSHFWLYHO\




¿[HG SDUDI¿QHPEHGGHG WLVVXH ))3( EORFNV ZKLFK
were retrieved from pathology archives were already 
available for this retrospective study. Tumour rich areas 
VHOHFWHGIRUFRQVWUXFWLRQRIWKH70$ZHUHLGHQWL¿HGE\
a consultant pathologist. Ethical approval for the use of 
WKLVWLVVXHZDVJUDQWHGE\WKHUHVHDUFK(WKLFV&RPPLWWHH
RI WKH1RUWK*ODVJRZ8QLYHUVLW\+RVSLWDOV1+67UXVW
1+6 **	& UHF QR  ,Q DFFRUGDQFH
ZLWK 5(0$5. FULWHULD WKH PDUNHUV H[DPLQHG VWXG\
REMHFWLYHV DQG K\SRWKHVLV ZDV GHVFULEHG 3DWLHQW
clinicopathological characteristics have been described, 
VSHFLPHQ FKDUDFWHULVWLFV SURYLGHG ,+& PHWKRGV DQG
DQWLERG\ VSHFL¿FLW\ FRQ¿UPHG %LRPDUNHUV KDYH EHHQ
shown in relation to prognostic variables and univariate 
and multivariate analysis applied.
,PPXQRKLVWRFKHPLVWU\
,PPXQRKLVWRFKHPLVWU\ ,+& ZDV SHUIRUPHG WR
DVVHVVSURWHLQOHYHOVRIPHPEHUVRIWKH1)ț%SDWKZD\V
,..ȕ DQG SKRVSKRU\ODWHG S VXEXQLW DW VHULQH 
RI 1)ț% SS 70$V ZHUH FXW LQWR ȝP WKLFN
VHFWLRQV WLVVXH ZDV GHZD[HG E\ LPPHUVLRQ LQ [\OHQH
and rehydrated through a series of graded alcohols. Heat 
Oncotarget33011www.impactjournals.com/oncotarget
induced antigen retrieval was performed in a solution 
RIHLWKHUFLWUDWHEXIIHUS+,..ȕRU7ULV('7$EXIIHU
S+SS7LVVXHZDVWKHQLQFXEDWHGLQK\GURJHQ
SHUR[LGH EHIRUH QRQVSHFL¿F ELQGLQJ ZDV EORFNHG E\
LQFXEDWLRQ LQ HLWKHU  QRUPDO KRUVH VHUXP VROXWLRQ
9HFWRU /DERUDWRULHV ,..ȕ RU [ FDHVLQ VROXWLRQ
9HFWRU/DERUDWRULHVSS6OLGHVZHUHWKHQLQFXEDWHG
LQ SULPDU\ DQWLERG\ RYHUQLJKW DW & ,..ȕ SS
Antibodies were diluted to optimal concentration in 
DQWLERG\GLOXHQW'DNR3ULPDU\DQWLERGLHVIRUDQWL,..ȕ
ZDV DE$EFDP DW  DQG IRU DQWL SS ZDV
DE$EFDPDW6WDLQLQJZDVGHYHORSHGXVLQJ
(Q9LVLRQ 'DNR DQG ¶GLDPLQREHQ]LGLQH '$%
9HFWRU/DERUDWRULHV+DUULV+DHPDWR[\OLQFRXQWHUVWDLQLQJ
was performed and tissue was dehydrated and mounted 
XVLQJ'3;
Stained TMA sections were scanned using a 
+DPDPDWVX 1DQR=RRPHU :HOZ\Q *DUGHQ &LW\
+HUWIRUGVKLUH8.DW[PDJQL¿FDWLRQDQGYLVXDOL]DWLRQ
ZDV FDUULHG RXW XVLQJ 6OLGHSDWK 'LJLWDO ,PDJH +XE
version 4.0.1 (Slidepath, Leica Biosystems, Milton 
.H\QHV 8. 3URWHLQ H[SUHVVLRQ ZDV DVVHVVHG XVLQJ
the weighted histoscore method [LB], with a second 
independent observer [JE] scoring 10% of cores and 





0&) DQG 0'$0% EUHDVW FDQFHU FHOOV
ZHUH FXOWXUHG LQ 'XOEHFFR¶V 0RGL¿HG (DJOH 0HGLXP
'0(0 /LIH 7HFKQRORJLHV ZLWK  )HWDO %RYLQH














O\VHG LQ SUHKHDWHG /DHPPOL¶V VDPSOH EXIIHU GLVSHUHG
E\UHSHDWLQJSDVVLQJWKURXJKD*QHHGOHDQGKHDWHGDW
100o&IRUPLQSULRUWRDQDO\VLV6'63RO\DFU\ODPLGH
*HO (OHFWURSKRUHVLV 6'63$*( ZDV SHUIRUPHG
to separate proteins, which were then transferred to 





FRQFHQWUDWLRQ LQ 1D77 EXIIHU FRQWDLQLQJ  ZY
%6$$QWLERGLHVDQGGLOXWLRQVXVHGZHUHDVIROORZVS
VF6DQWD&UX]SS 
&HOO 6LJQDOLQJ ,ț%Į   &HOO 6LJQDOLQJ
,..ȕDE$EFDPDQGȕWXEXOLQDW
DE$EFDP
0HPEUDQHV ZHUH LQFXEDWHG LQ VHFRQGDU\ +53
conjugated antibody (either rabbit or mouse, depending 
RQ SULPDU\ DQWLERG\ GLOXWHG  (QKDQFHG
FKHPLOXPLQHVFHQFH (&/ UHDJHQW ZDV XVHG WR GHWHFW
SUHVHQFHRIWKHDQWLERG\DQG;UD\¿OPVGHYHORSHGXVLQJ











and 300 nm was delivered to the cells using lipofectamine® 










plated for apoptosis or cell viability assays. Apoptosis 
OHYHOVZHUHDVVHVVHGXVLQJD&HOO'HDWK'HWHFWLRQHQ]\PH







were performed in triplicate and error bars representing 
standard deviation added to graphs. Fold change was 
compared to control.
&HOOYLDELOLW\YLD[&(//LJHQFH




measurements are continuously sent to the computer, 
allowing for real time growth curves to be plotted using 
³&HOO,QGH[´ZKLFKUHSUHVHQWVWKHQXPEHUDQGYLDELOLW\
RIWKHFHOOV>@&HOOVZHUHVHHGHGLQDZHOOE-plate 
$&($%LRVFLHQFHV6DQ'LHJRDW[3 cells/well with 
ȝORIPHGLDLQHDFKZHOOJURZQIRUWZRGD\VWRHQVXUH




21. Kaplan-Meier curves were constructed for cancer-
VSHFL¿F VXUYLYDO WKH ORJ UDQN WHVW ZDV HPSOR\HG WR
FRPSDUH KLJK DQG ORZ H[SUHVVLRQ +D]DUG UDWLRV ZHUH
FDOFXODWHG XVLQJ &R[ UHJUHVVLRQ ZLWK  FRQ¿GHQFH
LQWHUYDOV&R[UHJUHVVLRQPXOWLYDULDWHDQDO\VLVZDVDOVR
performed with the inclusion of known predictive factors. 
,QWHUUHODWLRQVKLSVEHWZHHQYDULDEOHVZHUHDVVHVVHGXVLQJ
contingency tables with the chi-squared test for trend as 
DSSURSULDWH9DOXHVRI3ZHUHFRQVLGHUHGVWDWLVWLFDOO\
VLJQL¿FDQW
Statistical analysis for apoptosis and cell viability 





:H JUDWHIXOO\ DFNQRZOHGJH &ODUH 2UDQJH ZKR
SURYLGHG WHFKQLFDO DVVLVWDQFH :H DOVR WKDQN WKH 1+6
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